Blueprint Medicines Corporation BPMC reported a loss of $2.20 per share for the third quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of $2.39. The company had incurred a loss of ...
Businesses that continually raise the bar, creating new paths of improvement with enthusiasm, build a company culture filled with high energy and a willingness to try new things. Most of all, ...
Blueprint Medicines Corporation BPMC reported a loss of $2.65 per share for fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $2.73. The company reported a $5.40 per share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results